{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:29:58Z","timestamp":1780734598349,"version":"3.54.1"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","award":["5X1000"],"award-info":[{"award-number":["5X1000"]}],"id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00740","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:37:01Z","timestamp":1565757421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives"],"prefix":"10.3389","volume":"9","author":[{"given":"Ilaria","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Sharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ciminale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3978\/j.issn.2225-319X.2012.11.04","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/blt.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3133\/cir1298","article-title":"Worldwide asbestos supply and consumption trends from 1900 through 2003","author":"Virta","year":"2006","journal-title":"Circular."},{"key":"B5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.ccr-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","article-title":"Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma","volume":"60","author":"Bograd","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-017-0644-5","article-title":"Liquid biopsy: a step forward towards precision medicine in urologic malignancies","volume":"16","author":"Di Meo","year":"2017","journal-title":"Mol Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/jco.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1038\/s41598-018-32315-3","article-title":"Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers","volume":"8","author":"Johnen","year":"2018","journal-title":"Sci Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De Rubis","year":"2019","journal-title":"Trends Pharmacol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1158\/0008-5472.can-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/jco.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1515\/cclm.2010.066","article-title":"Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels","volume":"48","author":"Rai","year":"2010","journal-title":"Clin Chem Lab Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"A potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.mp.0000056981.16578.c3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/s0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.ccr-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.ccr-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/1055-9965.epi-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Rodriguez Portal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00408-013-9526-9","article-title":"Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos","volume":"192","author":"Bayram","year":"2014","journal-title":"Lung."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lungcan.2011.02.007","article-title":"Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma\u2013which is best?","volume":"74","author":"Creaney","year":"2011","journal-title":"Lung Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/bjc.2015.286","article-title":"Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis","volume":"113","author":"Kirschner","year":"2015","journal-title":"Br J Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/mcp.0000000000000167","article-title":"Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma","volume":"21","author":"Creaney","year":"2015","journal-title":"Curr Opin Pulm Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.ccr-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc1213514","article-title":"Fibulin-3 as a biomarker for pleural mesothelioma","volume":"368","author":"Lamote","year":"2013","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1158\/1055-9965.epi-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1515\/cclm.2010.165","article-title":"Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population","volume":"48","author":"Park","year":"2010","journal-title":"Clin Chem Lab Med."},{"key":"B39","first-page":"1427","article-title":"Impact of renal failure on the tumor markers of mesothelioma, N-ERC\/mesothelin and osteopontin","volume":"31","author":"Shiomi","year":"2011","journal-title":"Anticancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/JTO.0b013e31820db377","article-title":"Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein\u2013a blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1378\/chest.07-0013","article-title":"Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma","volume":"132","author":"Creaney","year":"2007","journal-title":"Chest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1078-0432.ccr-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/jco.2009.26.9944","article-title":"Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J Clin Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/1078-0432.ccr-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer."},{"key":"B48","doi-asserted-by":"publisher","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/po.17.00282","article-title":"Megakaryocyte potentiating factor as a predictive biomarker for therapies against malignant mesothelioma","author":"Cao","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1078-0432.CCR-1405-2","article-title":"Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies","volume":"10","author":"Coppola","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.21037\/jtd.2017.12.17","article-title":"Biomarkers in the prevention and follow-up of workers exposed to asbestos","volume":"10","author":"Foddis","year":"2018","journal-title":"J Thorac Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMc1213514","article-title":"Fibulin-3 as a biomarker for pleural mesothelioma","volume":"368","author":"Pass","year":"2013","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax."},{"key":"B55","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/wnan.41","article-title":"Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos?","volume":"1","author":"Sanchez","year":"2009","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/j.1349-7006.2008.00853.x","article-title":"Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy","volume":"99","author":"Ono","year":"2008","journal-title":"Cancer Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1158\/1078-0432.ccr-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J Leukoc Biol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1158\/0008-5472.can-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Jube","year":"2012","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from cell death to New Life","volume":"6","author":"Venereau","year":"2015","journal-title":"Front Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(sici)1096-9896(199909)189:1<72::aid-path401>3.0.co;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and\u22122, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest."},{"key":"B66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","article-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","volume":"105","author":"Hirayama","year":"2011","journal-title":"Respir Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"Kao","year":"2012","journal-title":"Lung Cancer."},{"key":"B70","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/00365510260296492","article-title":"Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets","volume":"62","author":"Werther","year":"2002","journal-title":"Scand J Clin Lab Invest."},{"key":"B71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bille","year":"2016","journal-title":"J Thorac Oncol."},{"key":"B72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0891-5849(03)00060-1","article-title":"Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases","volume":"34","author":"Shukla","year":"2003","journal-title":"Free Radic Biol Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/carcin\/16.2.319","article-title":"The effect of iron binding on the ability of crocidolite asbestos to catalyze DNA single-strand breaks","volume":"16","author":"Hardy","year":"1995","journal-title":"Carcinogenesis."},{"key":"B74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0013-9351(85)90108-2","article-title":"Asbestos-induced decomposition of hydrogen peroxide","volume":"37","author":"Eberhardt","year":"1985","journal-title":"Environ Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/srep01123","article-title":"The interaction of asbestos and iron in lung tissue revealed by synchrotron-based scanning X-ray microscopy","volume":"3","author":"Pascolo","year":"2013","journal-title":"Sci Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/ars.2007.1909","article-title":"Iron homeostasis in the lung following asbestos exposure","volume":"10","author":"Ghio","year":"2008","journal-title":"Antioxid Redox Signal."},{"key":"B77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3978\/j.issn.2072-1439.2015.04.56","article-title":"MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/aps.2015.67","article-title":"Genome-wide analysis of microRNA and mRNA expression signatures in cancer","volume":"36","author":"Li","year":"2015","journal-title":"Acta Pharmacol Sin."},{"key":"B80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat Rev Clin Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-1-62703-453-1_8","article-title":"Isolation of circulating microRNA associated with RNA-binding protein","volume":"1024","author":"Turchinovich","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1073\/pnas.1100048108","article-title":"MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer","volume":"108","author":"Boeri","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/bjc.2016.151","article-title":"A circulating miRNA assay as a first-line test for prostate cancer screening","volume":"114","author":"Sharova","year":"2016","journal-title":"Br J Cancer."},{"key":"B84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/cancers10060203","article-title":"Biomarkers for early diagnosis and prognosis of malignant pleural mesothelioma: the quest goes on","volume":"10","author":"Ledda","year":"2018","journal-title":"Cancers."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS ONE."},{"key":"B86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clinbiochem.2012.02.009","article-title":"Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients","volume":"45","author":"Tomasetti","year":"2012","journal-title":"Clin Biochem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.lungcan.2015.09.021","article-title":"Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma","volume":"90","author":"Santarelli","year":"2015","journal-title":"Lung Cancer."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9645940","DOI":"10.1155\/2017\/9645940","article-title":"MicroRNA expression in malignant pleural mesothelioma and asbestosis: a pilot study","volume":"2017","author":"Mozzoni","year":"2017","journal-title":"Dis Markers."},{"key":"B89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13104-019-4113-7","article-title":"Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study","volume":"12","author":"Weber","year":"2019","journal-title":"BMC Res Notes."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e30221","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma\u2013a pilot study","volume":"7","author":"Weber","year":"2012","journal-title":"PLoS ONE."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e114483","DOI":"10.1371\/journal.pone.0114483","article-title":"Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis","volume":"9","author":"Weber","year":"2014","journal-title":"PLoS ONE."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0176680","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS ONE."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1002\/jcb.27586","article-title":"Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma","volume":"120","author":"Matboli","year":"2019","journal-title":"J Cell Biochem"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1038\/emm.2013.81","article-title":"U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis","volume":"45","author":"Benz","year":"2013","journal-title":"Exp Mol Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"984","DOI":"10.4149\/neo_2016_618","article-title":"A potential biomarker for colorectal cancer: long non-coding RNA RP1-13P20.6","volume":"63","author":"Liu","year":"2016","journal-title":"Neoplasma"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1010428317694563","DOI":"10.1177\/1010428317694563","article-title":"Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma","volume":"39","author":"Hu","year":"2017","journal-title":"Tumour Biol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2006.05.034","article-title":"DRAM, a p53-induced modulator of autophagy, is critical for apoptosis","volume":"126","author":"Crighton","year":"2006","journal-title":"Cell."},{"key":"B100","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1373\/clinchem.2010.144188","article-title":"Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing","volume":"56","author":"Fan","year":"2010","journal-title":"Clin Chem."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med."},{"key":"B103","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/1471-2407-12-428","article-title":"Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas","volume":"12","author":"Sriram","year":"2012","journal-title":"BMC Cancer."},{"key":"B105","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet."},{"key":"B106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","article-title":"Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients","volume":"124","author":"Hylebos","year":"2018","journal-title":"Lung Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2013.05.014","article-title":"The role of epigenetics in malignant pleural mesothelioma","volume":"81","author":"Vandermeers","year":"2013","journal-title":"Lung Cancer."},{"key":"B108","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fcell.2014.00049","article-title":"Epigenetics across the human lifespan","volume":"2","author":"Kanherkar","year":"2014","journal-title":"Front Cell Dev Biol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2016.05.023","article-title":"Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy","volume":"107","author":"Tomasetti","year":"2017","journal-title":"Lung Cancer."},{"key":"B110","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jtho.2018.10.163","article-title":"Peripheral blood DNA methylation as potential biomarker of malignant pleural mesothelioma in asbestos-exposed subjects","volume":"14","author":"Guarrera","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1159\/000345182","article-title":"Circulating tumor cells in lung cancer","volume":"56","author":"Young","year":"2012","journal-title":"Acta Cytol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.21037\/tlcr.2017.05.08","article-title":"Biophysical technologies for understanding circulating tumor cell biology and metastasis","volume":"6","author":"Su","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1517\/17530059.2012.676042","article-title":"Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma","volume":"6","author":"Pinton","year":"2012","journal-title":"Expert Opin Med Diagn."},{"key":"B114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/cbm-140448","article-title":"Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma","volume":"15","author":"Raphael","year":"2015","journal-title":"Cancer Biomark."},{"key":"B115","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1245\/s10434-013-3399-2","article-title":"Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM)","volume":"4","author":"Yoneda","year":"2014","journal-title":"Ann Surg Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/or.2016.5235","article-title":"EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'","volume":"37","author":"Chikaishi","year":"2017","journal-title":"Oncol Rep."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1043\/1543-2165-133.8.1317","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group","volume":"133","author":"Husain","year":"2009","journal-title":"Arch Pathol Lab Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/cas.13895","article-title":"Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma","volume":"110","author":"Yoneda","year":"2019","journal-title":"Cancer Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1078-0432.ccr-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/JTO.0b013e3182460fa9","article-title":"Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed","volume":"7","author":"Christoph","year":"2012","journal-title":"J Thorac Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cllc.2015.01.004","article-title":"Phase I study of lapatinib and pemetrexed in the second-line treatment of advanced or metastatic non-small-cell lung cancer with assessment of circulating cell free thymidylate synthase RNA as a potential biomarker","volume":"16","author":"Ramlau","year":"2015","journal-title":"Clin Lung Cancer."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T00:38:20Z","timestamp":1569112700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":121,"alternative-id":["10.3389\/fonc.2019.00740"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00740","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"article-number":"740"}}